MAR 26, 2017 10:38 AM PDT

Lab-Grown Blood Now Possible to Mass-Produce

WRITTEN BY: Xuan Pham

Lab-grown red blood cells are not a new concept. But culturing enough of these cells in mass quantities was the main challenge. Now researchers from the University of Bristol and NHS Blood and Transplant say they’ve developed a new technique that would enable mass production of man-made blood.

According to the American Red Cross, nearly 21 million blood components are transfused every year in the U.S. They also estimate that someone is in need of a blood transfusion every 2 seconds. With such a high demand for blood, there’s significant shortage of this precious liquid despite many donors and increasing blood drive efforts.

To solve this problem, scientists turned to the lab, where they hoped to create lab-grown red blood cells to alleviate the shortage. Conventional methods of transforming stem cells into red blood cells were successful, except when it came to actual practice. The stem cells are good for no more than 50,000 red blood cells before it dies. For reference, a bag of blood contains about one trillion red blood cells. In effect, this was a very limited production method that still required frequent donation.

But what if the stem cells can be immortalized? That is, what if these cells can be eternally trapped in an early stage where they can grow without burning out? Then, scientists will have endless supplies of premature red cells at their disposal for coaxing into mature red blood cells.

Indeed, scientists at the University of Bristol figured out exactly how to immortalize a line of cells, which are now capable of providing a continuous supply of red blood cells. "We have demonstrated a feasible way to sustainably manufacture red cells for clinical use,” said Jan Frayne, the study’s senior author. "We've grown liters of it."

The next hurdle is to scale it up for clinics and hospitals. "There is a bioengineering challenge,” said David Anstee, the study’s co-author. "To produce that much at scale is quite a challenge, and really the next phase of our work is to look at methods of expanding the yield." Anstee admits the cost of mass-producing blood is a main concern.

However, that there is now a method to mass-produce blood is already a significant achievement. "The first therapeutic use of a cultured red cell product is likely to be for patients with rare blood groups, because suitable conventional red blood cell donations can be difficult to source,” said Anstee. Lab-grown blood cells may also benefit patients with blood disorders that require many transfusions. And because it’s lab-grown, the blood will carry fewer risks for transmissible diseases, which may make it ideal for parts of the world where the blood supply has high contamination rates.

Additional sources: BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
DEC 10, 2020
Clinical & Molecular DX
Gut Feeling: Microbiome Reveals Toxic Chemical Exposure in Kids
DEC 10, 2020
Gut Feeling: Microbiome Reveals Toxic Chemical Exposure in Kids
A study by Duke University researchers has revealed that children’s gut microbiomes hold clues as to their possibl ...
DEC 22, 2020
Cardiology
A New 3D Imaging Method for Atherosclerosis Analysis in Mice
DEC 22, 2020
A New 3D Imaging Method for Atherosclerosis Analysis in Mice
Imaging in research may not sound glamorous, but how else would news stories get those cool looking science photos for t ...
JAN 07, 2021
Clinical & Molecular DX
Breath of Life: Nighttime Respiratory Rates Identify Which Heart Patients Need Surgery
JAN 07, 2021
Breath of Life: Nighttime Respiratory Rates Identify Which Heart Patients Need Surgery
Cardiovascular disease is the leading cause of death worldwide, taking nearly 18 million lives every year. Of these card ...
FEB 03, 2021
Immunology
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
FEB 03, 2021
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
Researchers are still studying how long a person can stay immune against COVID-19 following infection. A new study by a ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
Loading Comments...